SEC Form 4 · accession 0001963901-26-000003
Mineralys Therapeutics, Inc. · MLYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian Taylor Slingsby
Director
Period of report
Sep 22, 2026
Accepted (ET)
Sep 24, 2026 · 9:49 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001933414
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Sep 22, 2026 | S | 104,320 | $28.8085 | D | 7,805,718 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of common stock sold by Catalys Pacific Fund, LP. See footnote (3).
- F2The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $28.700 to $28.905. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3Represents shares of common stock held of record by Catalys Pacific Fund, LP. Catalys Pacific Fund GP, LP is the general partner of Catalys Pacific Fund, LP. Catalys Pacific, LLC is the general partner of Catalys Pacific Fund GP, LP, and Mr. Slingsby is the managing partner of Catalys Pacific, LLC. Accordingly, Mr. Slingsby may be deemed to share voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Mr. Slingsby disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.